Patents Assigned to Aventis Pasteur, Inc
  • Publication number: 20100278848
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Application
    Filed: April 15, 2004
    Publication date: November 4, 2010
    Applicant: AVENTIS PASTEUR, INC.
    Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Laszlo Radvanyi, Devender Singh-Sandhu
  • Publication number: 20090156519
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Application
    Filed: December 23, 2004
    Publication date: June 18, 2009
    Applicants: AVENTIS PASTEUR, INC., THERION BIOLOGICS, INC.
    Inventors: Neil Berinstein, James Tartaglia, Mark Parrington, Dennis Panicali, Linda Gritz
  • Patent number: 7018637
    Abstract: Multivalent immunogenic molecules comprise a carrier molecule containing at least one functional T-cell epitope and multiple different carbohydrate fragments each linker to the carrier molecule and each containing at least one functional B-cell epitope. The carrier molecule inputs enhanced immunogenicity to the multiple carbohydrate fragments. The carbohydrate fragments may be capsular oligosaccharide fragments from Streptococcus pneumoniae, which may be serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F or 23F, or Neisseria meningitidis, which may be serotype A, B, C, W-135 or Y. Such oligosaccharide fragments may be sized from 2 to 5 kDa. Alternatively, the carbohydrate fragments may be fragments of carbohydrate-based tumor antigens, such as Globo H, LeY or STn. The multivalent molecules may be produced by random conjugation or site-directed conjugation of the carbohydrate fragments to the carrier molecule.
    Type: Grant
    Filed: February 23, 1998
    Date of Patent: March 28, 2006
    Assignee: Aventis Pasteur, Inc
    Inventors: Pele Chong, Alf Lindberg, Michel Klein
  • Publication number: 20060002946
    Abstract: The present invention provides reagents and methods for producing and utilizing targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.
    Type: Application
    Filed: December 30, 2004
    Publication date: January 5, 2006
    Applicant: Aventis Pasteur, Inc.
    Inventors: William Scott Gallichan, Robert Uger, Marie-Danielle Salha
  • Publication number: 20040170646
    Abstract: The present invention relates to methods for producing ALVAC virus on avian embryonic stem cells and compositions comprising ALVAC virus made using such methods.
    Type: Application
    Filed: December 12, 2003
    Publication date: September 2, 2004
    Applicant: Aventis Pasteur, Inc.
    Inventors: Veronique Barban, Luc Aujame
  • Patent number: 6146902
    Abstract: Disclosed and claimed are a method for the purification of polysaccharide-protein conjugate vaccines by ultrafiltration in a saturated solution of ammonium sulfate. The ultrafiltration method of the present invention provides an efficient, readily scalable method for removal of unbound polysaccharides from polysaccharide-protein vaccines, thereby improving the purity and consistency of the polysaccharide-protein vaccines.
    Type: Grant
    Filed: December 29, 1998
    Date of Patent: November 14, 2000
    Assignee: Aventis Pasteur, Inc.
    Inventor: Ronald McMaster